To the Editor.
—I was concerned when I read the account in the Archives by Germain et al1 of attempted lead chelation therapy in an elderly patient with progressive renal insufficiency. Several factors that could have either explained or contributed to this condition were cited, including lead "exposure," the extent or magnitude of which was not specified.Even though the initial blood lead level was only 10 μg/dL of blood, the authors administered edetic acid (EDTA), allegedly to improve the patient's renal function. It is not clear why the authors perceived that increasing the renal lead burden would help seriously compromised kidneys. Indeed, the Occupational Safety and Health Administration, in its lead standard, condemns the administration of this agent in lead-exposed individuals under circumstances other than those in which the overriding medical concern justifies the wellknown renal risks associated with the drug's administration. Edetic acid itself is nephrotoxic, as
Sawyer HJ. Chelation Therapy in Lead Nephropathy Questioned. Arch Intern Med. 1985;145(10):1927. doi:https://doi.org/10.1001/archinte.1985.00360100201040
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: